Over 17% of patients with no use of antidiabetic medications at baseline started at least one such drug after initiating a PI3Kα, AKT and Pan‐PI3K inhibitors and 4.5% patients required multiple agents to manage hyperglycemia. This evidence concerns the gene AKT1 and Hyperglycemia.